Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Friday 9 October →